Bioprinting is advancing rapidly, offering new ways to model disease, develop drugs, and engineer human tissue. Yet as scientific capabilities accelerate, healthcare systems, regulatory frameworks, and clinical pathways often struggle to keep pace. In this one-on-one fireside chat, Tamer Mohamed, Founder and CEO of Aspect Biosystems, examines where bioprinting truly stands today, what is already being tested, what remains out of reach, and what it takes to translate complex biofabrication science into real-world impact.